UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~May~~July ~~17th~~8, 2019

~~BLAKE~~BIOHEMP ~~INSOMNIA THERAPEUTICS~~INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter)

Nevada

000-55022

46-0780380

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

244 5^th Avenue Suite A-154

New York, NY 10001

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: ~~+1-~~646-453-4912

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 51.01 ~~Changes~~Entry ininto ~~Control~~a ofMaterial ~~Registrant.~~Definitive Agreement

~~Reference~~On isMarch ~~made~~8, to2019, ~~the~~BioHemp ~~disclosure~~International, ~~set~~Inc., ~~forth~~formerly ~~under~~Blake ~~Items~~Insomnia 1Therapeutics, Inc.01 ~~and~~(the ~~5.02~~“Company”), ofentered ~~this~~into ~~Report~~an Assignment Agreement (the “Assignment Agreement”), ~~which~~with ~~disclosure~~FJ isInvestments ~~incorporated~~International, ~~herein~~Inc., bya ~~reference~~Utah corporation (“FJ”).

~~Item~~Pursuant ~~5.02~~to ~~Departure~~the ofAssignment ~~Directors~~Agreement, orFJ ~~Certain~~assigned ~~Officers;~~to ~~Election~~the ofCompany ~~Directors;~~the ~~Appointment~~rights to certain intellectual property (the “Assigned IP”) associated with the manufacture of ~~Certain~~CBD ~~Officers~~infused water. FJ had obtained the rights to the Assigned IP pursuant to a License Agreement dated February 21, 2019 (the “License Agreement”), between FJ and American Premium Water Corporation, a Nevada corporation (“HIPH”). Additionally, pursuant to the Assignment Agreement, FJ assigned assets relating to the BioHempInternational.com domain.

OnIn ~~May~~consideration ~~15,~~of ~~2019,~~ the ~~board~~assignment of ~~directors (~~the ~~“Board”)~~assets ofand ~~Blake~~the ~~Insomnia~~Assigned ~~Therapeutics~~IP, ~~Inc., (~~the “Company”) ~~voted~~agreed to ~~increase~~issue ~~the~~twenty-five ~~size~~million ~~of the Board from one director to two directors~~(25,000,000) ~~and~~shares ~~to recommend that the shareholders~~ of the Company’s ~~elect~~common ~~Daniel~~stock ~~Blum~~ to ~~serve~~FJ ~~as a member of~~ (the ~~Board~~“FJ Shares”).

~~Further,~~Pursuant onto ~~May~~the ~~15,~~Assignment ~~2019~~Agreement, the ~~majority shareholder of the~~ Company ~~(the~~must ~~“Shareholder”)~~abide ~~elected~~by ~~Daniel~~all ~~Blum~~terms toof ~~serve~~the onLicense ~~the~~Agreement ~~Board~~between ofFJ ~~the~~and ~~Company~~HIPH.

~~Additionally,~~On onJuly ~~May 15~~10, 2019, ~~Daniel Cattlin,~~ the Company’s ~~President,~~transfer ~~Chief~~agent ~~Executive~~delivered ~~Officer,~~the ~~Treasurer,~~certificate ~~and~~representing ~~a member of~~ the ~~Board,~~FJ ~~submitted~~Shares to ~~the~~FJ ~~Company his resignation letter~~ pursuant to ~~which he resigned from his positions as President, Chief Executive Officer, Treasurer, and member of~~ the ~~Board.~~Assignment MrAgreement. ~~Cattlin’s resignation was not a result of any disagreements relating to the Company’s operations, policies or practices.~~

~~Also,~~The onAssignment ~~May~~Agreement ~~15,~~contains ~~2019~~standard and customary representations, ~~the~~warranties ~~Board~~and ~~accepted~~covenants. ~~the~~The ~~resignation~~foregoing ofdescription ~~Daniel~~does ~~Cattlin~~not purport to be complete and ~~appointed~~is ~~Daniel~~qualified ~~Blum~~in toits ~~serve~~entirety asby reference to the ~~President~~Assignment Agreement, ~~Chief~~a ~~Executive~~copy ~~Officer,~~of ~~Secretary,~~which is filed as Exhibit 10.1 to this Current Report on Form 8-K and ~~Treasurer~~incorporated ofherein ~~the~~by ~~Company~~reference.

~~Daniel~~Item ~~Blum,~~3.02 ~~30,~~Unregistered ~~President,~~Sales ~~Chief~~of ~~Executive~~Equity ~~Officer, Secretary, Treasurer, and Director~~Securities.

~~Mr.~~The ~~Blum~~information ~~started~~set ~~work~~forth asin aItem ~~Business Development Manager at Starwood Hotels Worldwide~~1.01 Heof ~~worked~~this ~~jointly~~Current ~~with~~Report ~~all New York Starwood Hotels to find new partnership opportunities. Assisted in bringing~~ on ~~new~~Form ~~business~~8-K ~~and~~is ~~collaborating~~incorporated ~~with~~herein ~~operations~~by ~~and sales to ensure the desired startup exceeding the customer standards~~reference.

~~Mr.~~The ~~Blum~~issuance ~~then~~of ~~went~~the FJ Shares was completed in reliance on toexemptions ~~work~~from atregistration ~~Preqin,~~under Section 4(a)(2) ~~provider~~ of ~~market~~the ~~research~~Securities ~~and~~Act. ~~analytics~~This totransaction ~~alternative~~qualified ~~asset~~for ~~managers~~exemption ~~and~~from ~~investors~~registration tobecause ~~assist~~(i) ~~them~~the ~~with~~Company ~~return-on-investment~~did ~~opportunities.~~not Heengage ~~helped~~in ~~secure~~any ageneral ~~wide~~solicitation ~~range~~or ofadvertising ~~business~~to ~~from~~market ~~investment~~the ~~banks,~~securities; ~~private~~(ii) ~~equity~~FJ ~~firms,~~was ~~private~~provided ~~debt,~~the ~~hedge~~opportunity ~~funds~~to ask questions and ~~consulting~~receive ~~firms~~answers tofrom ~~name~~the ~~but~~Company aregarding ~~few.~~its ~~Presented~~business aand ~~weekly~~the ~~economic~~issuance; ~~briefing~~(iii) the FJ Shares were issued to ~~the~~an ~~team;~~investor ~~containing~~with USknowledge ~~macroeconomic,~~and ~~foreign~~experience ~~exchange~~in ~~rate,~~financial and ~~international~~business ~~commodities~~matters ~~analysis.~~so ~~Working~~that ~~with~~it ~~Preqin’s~~was ~~product~~capable ~~team,~~of heevaluating ~~designed~~the merits and ~~built~~risks aof ~~sustainable~~an ~~product~~investment ~~and~~in ~~pricing~~the ~~model~~Company; ~~for~~and (iv) the USrecipient ~~market,~~received ~~giving~~“restricted ~~him~~securities” that include a ~~comprehensive~~restrictive ~~understanding~~legend ofon the ~~financial~~certificate, ~~legal,~~which ~~and~~restricts ~~compliance~~the ~~procedures~~FJ ~~involved~~Shares infrom being transferred except pursuant to a registration statement that is effective with the ~~business~~SEC ~~sector.~~or pursuant to an exemption from registration.

MrItem 7.01 ~~Blum~~Regulation ~~then~~FD worked as an Account Executive at Salesforce (NYSE: CRM | Market Cap £122B), where he developed his negotiation skills selling salesforce’s SaaS platform consisting of Sales, Customer Service, Marketing, Platform (PaaS), Analytics, Artificial Intelligence, and Team Collaboration solutions, advising high-growth, early-stage start-ups on the value of the PlatformDisclosure.

~~Mr.~~Press Blum then went to work for Pitchbook as a business development executive. Pitchbook SaaS delivers data, research, and technology covering the private capital markets, including venture capital, private equity, and M&A transactions. Release

~~Family~~On ~~Relationships~~July 8, 2019, the Company issued a press release relating to the Assignment Agreement and the Company’s plans to distribute CBD-infused water utilizing HIPH’s proprietary Hydro Nano technology.

~~There~~A ~~are~~copy noof ~~family~~the ~~relationships~~press ~~between~~release Mris included as Exhibit 99.1 ~~Blum~~to this Current Report, and ~~any~~the ~~previous~~press ~~officers~~release orwill ~~directors~~be deemed to be “furnished” rather than “filed,” pursuant to the rules of the ~~Company~~Securities and Exchange Commission.

Related Party Transactions

There are no related party transactions reportable under Item 5.02 of Form 8-K or Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit No.		Description

10.1		Form of Assignment Agreement dated as of March 8, 2019, by and among Blake Insomnia Therapeutics, Inc. and FJ Investments International, Inc.

99.1		The Press release dated July 8, 2019 “BioHemp International, Inc. (OTC: BKIT) Announces Deal to Private Label Water From American Premium Water Corporation (OTC: HIPH)”

Exhibit Number		Description
17		Letter of Resignation, dated May 15, 2019 by Daniel Cattlin.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Blake Insomnia Therapeutics, Inc.
	Blake Therapeutics, Inc.
Dated: May 17, 2019	By:	/s/ Daniel Blum
Dated: July 11, 2019	By:	/s/ Daniel Blum
	Name:	Daniel Blum
	Title:	President

Filing Compare · BIOHEMP INTERNATIONAL, INC.